PRICING SHEET TEMPLATE - Attachment 1.xlsx

XLSX spreadsheet 22 KB Posted

Attached to
Evaluation of Abuse Potential of Synthetic Cannabinoids and Phytocannabinoids Using In Vivo Pharmacological Studies
Solicitation number
15DDHQ25Q00000010
Issued by

About this file

This is a Pricing Sheet Template for a Drug Enforcement Administration (DEA) contract opportunity focused on evaluating the abuse potential of various substances through in vivo pharmacological studies. The document outlines pricing details for five distinct ordering periods, with each period structured identically and covering multiple types of scientific assays: Locomotor Activity Assay, Drug Discrimination Assay, and Cannabinoid Tetrad Assay. Each ordering period involves testing 17 total drugs (15 test drugs and 2 reference drugs), with specific line items for assay costs, incidental costs, and drug costs.

The first ordering period is specifically for evaluating synthetic opioids, while the subsequent four ordering periods are dedicated to studying hallucinogenic substances. Although the pricing template shows zero dollar amounts, it provides a standardized framework for potential contractors to complete with their specific pricing. The contract opportunity (Solicitation Number 15DDHQ25Q00000010) is issued by the Department of Justice's Drug Enforcement Administration and seeks investigational study results and methodology descriptions for abuse potential assessments of synthetic cannabinoids and phytocannabinoids using in vivo pharmacological studies.

View the file

Other files

File Type Posted
15DDHQ25Q00000010 Amendment 0001 03192025.pdf PDF
Pricing Sheet Templalte.xlsx XLSX spreadsheet
RFQ 15DDHQ25Q00000010.pdf PDF
Sample BPA Call Order - Attachment 2.xlsx XLSX spreadsheet

On GovTribe

Work with this file

  • Download the original file
  • Contacts named in this file
  • Similar government files
  • Ask GovTribe AI about this file

Text version

Summary

PERIODTotal Cost Per Ordering Period
ORDERING PERIOD 1$ - 0
ORDERING PERIOD 2$ - 0
ORDERING PERIOD 3$ - 0
ORDERING PERIOD 4$ - 0
ORDERING PERIOD 5$ - 0
Total Cost$ - 0

ORDERING PERIOD 1

PRICING SHEET TEMPLATE: ATTACHMENT 1
Title:Evaluation of Abuse Potential of Synthetic Opioids and Other Depressants Using In Vivo Pharmacological Studies
Agency:Drug Enforcement Administration
ORDERING PERIOD 1
CLIN Line ItemAssayQuantityUnitUnit PriceEstimated Total Price
1Locomotor Activity Assay Cost10EA$ - 0
Locomotor Activity Assay Incidental Cost10EA$ - 0
2Drug Discrimination (monthly maintenance of training drug) Assay Cost3EA$ - 0
Drug Discrimination (training drug) Incidental Cost3EA$ - 0
Drug Discrimination of test drug Assay Cost10EA$ - 0
3Drug Discrimination of test drug Incidental Cost10EA$ - 0
Cannabinoid Tetrad Assay10EA$ - 0
4Cannabinoid Tetrad Assay incidental cost10EA$ - 0
5Drug Cost Not to Exceed10EA$ - 0
TOTAL COST ($)$ - 0
** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS
1 TOTAL

ORDERING PERIOD 2

PRICING SHEET TEMPLATE: ATTACHMENT 1
Title:Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies
Agency:Drug Enforcement Administration
ORDERING PERIOD 2
CLIN Line ItemAssayQuantityUnitUnit PriceEstimated Total Price
1001Locomotor Activity Assay Cost10EA$ - 0
Locomotor Activity Assay Incidental Cost10EA$ - 0
1002Drug Discrimination (monthly maintenance of training drug) Assay Cost3EA$ - 0
Drug Discrimination (training drug) Incidental Cost3EA$ - 0
Drug Discrimination of test drug Assay Cost10EA$ - 0
1003Drug Discrimination of test drug Incidental Cost10EA$ - 0
Cannabinoid Tetrad Assay10EA$ - 0
1004Cannabinoid Tetrad Assay incidental cost10EA$ - 0
1005Drug Cost Not to Exceed10EA$ - 0
TOTAL COST ($)$ - 0
** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS

ORDERING PERIOD 3

PRICING SHEET TEMPLATE: ATTACHMENT 1
Title:Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies
Agency:Drug Enforcement Administration
ORDERING PERIOD 3
CLIN Line ItemAssayQuantityUnitUnit PriceEstimated Total Price
2001Locomotor Activity Assay Cost10EA$ - 0
Locomotor Activity Assay Incidental Cost10EA$ - 0
2002Drug Discrimination (monthly maintenance of training drug) Assay Cost3EA$ - 0
Drug Discrimination (training drug) Incidental Cost3EA$ - 0
Drug Discrimination of test drug Assay Cost10EA$ - 0
2003Drug Discrimination of test drug Incidental Cost10EA$ - 0
Cannabinoid Tetrad Assay10EA$ - 0
2004Cannabinoid Tetrad Assay incidental cost10EA$ - 0
2005Drug Cost Not to Exceed10EA$ - 0
TOTAL COST ($)$ - 0
** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS

ORDERING PERIOD 4

PRICING SHEET TEMPLATE: ATTACHMENT 1
Title:Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies
Agency:Drug Enforcement Administration
ORDERING PERIOD 4
CLIN Line ItemAssayQuantityUnitUnit PriceEstimated Total Price
3001Locomotor Activity Assay Cost10EA$ - 0
Locomotor Activity Assay Incidental Cost10EA$ - 0
3002Drug Discrimination (monthly maintenance of training drug) Assay Cost3EA$ - 0
Drug Discrimination (training drug) Incidental Cost3EA$ - 0
Drug Discrimination of test drug Assay Cost10EA$ - 0
3003Drug Discrimination of test drug Incidental Cost10EA$ - 0
Cannabinoid Tetrad Assay10EA$ - 0
3004Cannabinoid Tetrad Assay incidental cost10EA$ - 0
3005Drug Cost Not to Exceed10EA$ - 0
TOTAL COST ($)$ - 0
** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS

ORDERING PERIOD 5

PRICING SHEET TEMPLATE: ATTACHMENT 1
Title:Evaluation of Abuse Potential of Hallucinogenic Substances Using In Vivo Pharmacological Studies
Agency:Drug Enforcement Administration
ORDERING PERIOD 5
CLIN Line ItemAssayQuantityUnitUnit PriceEstimated Total Price
4001Locomotor Activity Assay Cost10EA$ - 0
Locomotor Activity Assay Incidental Cost10EA$ - 0
4002Drug Discrimination (monthly maintenance of training drug) Assay Cost3EA$ - 0
Drug Discrimination (training drug) Incidental Cost3EA$ - 0
Drug Discrimination of test drug Assay Cost10EA$ - 0
4003Drug Discrimination of test drug Incidental Cost10EA$ - 0
Cannabinoid Tetrad Assay10EA$ - 0
4004Cannabinoid Tetrad Assay incidental cost10EA$ - 0
4005Drug Cost Not to Exceed10EA$ - 0
TOTAL COST ($)$ - 0
** NOTE: 15 Test Drugs + 2 Reference Drugs = 17 TOTAL DRUGS

File details come from the government source that posted it. Updated .